US 11,707,510 B2
Nucleic acid-based botulinum neurotoxin for therapeutic use
Jonas Füner, Potsdam (DE)
Assigned to PRECLINICS DISCOVERY GMBH, Potsdam (DE)
Appl. No. 16/970,320
Filed by preclinics discovery GmbH, Potsdam (DE)
PCT Filed Feb. 18, 2019, PCT No. PCT/EP2019/053937
§ 371(c)(1), (2) Date Aug. 14, 2020,
PCT Pub. No. WO2019/158745, PCT Pub. Date Aug. 22, 2019.
Claims priority of application No. 10 2018 103 504.7 (DE), filed on Feb. 16, 2018.
Prior Publication US 2021/0077597 A1, Mar. 18, 2021
Int. Cl. A61K 38/48 (2006.01)
CPC A61K 38/4893 (2013.01) [C12Y 304/24069 (2013.01)] 14 Claims
 
1. A nucleic acid for use as a drug and/or in therapeutic methods comprising a botulinum neurotoxin (BoNT)-encoding nucleic acid sequence, wherein the BoNT-encoding nucleic acid sequence is modified such that the linker region in the encoded protein between the light and heavy chains comprises a recognition motif for a protease and wherein the BoNT-encoding nucleic acid sequence, excluding the recognition motif for the protease, comprises a sequence according to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 or a sequence having 80% sequence identity thereto.